BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22342538)

  • 1. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.
    Bateman ED; Bleecker ER; Lötvall J; Woodcock A; Forth R; Medley H; Davis AM; Jacques L; Haumann B; Busse WW
    Respir Med; 2012 May; 106(5):642-50. PubMed ID: 22342538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW; Bleecker ER; Bateman ED; Lötvall J; Forth R; Davis AM; Jacques L; Haumann B; Woodcock A
    Thorax; 2012 Jan; 67(1):35-41. PubMed ID: 21828231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
    Bleecker ER; Bateman ED; Busse WW; Woodcock A; Frith L; House KW; Jacques L; Davis AM; Haumann B; Lötvall J
    Ann Allergy Asthma Immunol; 2012 Nov; 109(5):353-358.e4. PubMed ID: 23062392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily.
    Kerwin EM; Nathan RA; Meltzer EO; Ortega HG; Yancey SW; Schoaf L; Dorinsky PM
    Respir Med; 2008 Apr; 102(4):495-504. PubMed ID: 18206361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily evening administration of mometasone furoate in asthma treatment initiation.
    Bensch GW; Prenner B; Berkowitz R; Galant S; Ramsdell J; Lutsky B
    Ann Allergy Asthma Immunol; 2006 Apr; 96(4):533-40. PubMed ID: 16680923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
    Galant SP; van Bavel J; Finn A; Gross G; Pleskow W; Brown A; Hamedani AG; Harding SM
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial.
    Sterling R; Lim J; Frith L; Snowise NG; Jacques L; Haumann B
    Respir Med; 2012 Aug; 106(8):1110-5. PubMed ID: 22520084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial.
    Busse WW; Bateman ED; O'Byrne PM; Lötvall J; Woodcock A; Medley H; Forth R; Jacques L
    Allergy; 2014 Nov; 69(11):1522-30. PubMed ID: 25040613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.
    Lee LA; Yang S; Kerwin E; Trivedi R; Edwards LD; Pascoe S
    Respir Med; 2015 Jan; 109(1):54-62. PubMed ID: 25452139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate.
    Rojas RA; Paluga I; Goldfrad CH; Duggan MT; Barnes N
    J Asthma; 2007; 44(6):437-41. PubMed ID: 17654129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
    Wasserman RL; Baker JW; Kim KT; Blake KV; Scott CA; Wu W; Faris MA; Crim C
    Ann Allergy Asthma Immunol; 2006 Jun; 96(6):808-18. PubMed ID: 16802768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
    O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
    Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial.
    Busse W; Raphael GD; Galant S; Kalberg C; Goode-Sellers S; Srebro S; Edwards L; Rickard K;
    J Allergy Clin Immunol; 2001 Mar; 107(3):461-8. PubMed ID: 11240946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.